U.S., April 30 -- ClinicalTrials.gov registry received information related to the study (NCT07555470) titled 'Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular Lymphoma' on April 13.
Brief Summary: The purpose of this prospective, multicenter, Phase 2 study is to evaluate the efficacy and safety of Mosunetuzumab in combination with the EZH2 inhibitor Zeprumetostat (SHR2554) in patients with follicular lymphoma (FL). The study plans to enroll approximately 80 patients, who will be assigned to three distinct cohorts: previously untreated high-risk FL (Cohort 1), previously untreated low-tumor-burden FL (Cohort 2), and relapsed or refractory FL (Cohort 3). The study consists of a safety run-in phase, which will be initially...